Vectorology - GEG Tech top picks

The past several years have seen tremendous advances in the engineering of immune
effector cells as therapy for cancer. While chimeric antigen receptors (CARs) have
been used extensively to redirect the specificity of autologous T cells against hematological
malignancies with striking clinical results, studies of CAR-modified natural killer
(NK) cells have been largely preclinical. In this review, we focus on recent advances
in NK cell engineering, particularly on preclinical evidence suggesting that NK cells
may be as effective as T cells in recognizing and killing targets after genetic modification.